Skip to content

Evaluation of Diet and Exercise in Patients With Non-Alcoholic Fatty Liver Disease

Prospective Histopathologic Evaluation of Diet and Exercise in Patients With Non-Alcoholic Fatty Liver Disease

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00815009
Acronym
NAFLD
Enrollment
56
Registered
2008-12-29
Start date
2008-10-31
Completion date
2010-12-31
Last updated
2012-07-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fatty Liver

Keywords

NAFLD, NASH

Brief summary

Moderate exercise with a low fat and/or a moderate fat with low processed carbohydrate diet will have a greater effect on slowing disease progression and reversing hepatic steatosis and/or necro-inflammation in the liver of adult patients with NAFLD and NASH when compared to a regular healthy diet alone.

Interventions

BEHAVIORALMod Fat/Low Processed Carb Diet and Moderate Exercise

Follow a moderate fat with low processed carbohydrate diet with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)

BEHAVIORALLow Fat Diet and Moderate Exercise

Follow a low fat diet along with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)

BEHAVIORALModerate Exercise Only

No special dietary meal plan. Moderate exercise in the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)

Sponsors

San Antonio Military Medical Center
Lead SponsorFED

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* Age 18-70 yrs * DEERS eligible (DoD beneficiary) * All participants must plan to be in the area for at least nine months * Liver biopsy confirmed NAFLD/NASH (NAS Score evaluating steatosis, lobular inflammation and hepatocyte ballooning) within the past 6 months

Exclusion criteria

* Alcohol consumption \> 20 g/d or history of alcohol abuse * Hepatitis A, B, C * Chronic liver disease of any other etiology * Fatty acid oxidation disorder (Inborn errors of metabolism) * Insulin therapy regime for treatment of diabetes * Pregnancy

Design outcomes

Primary

MeasureTime frame
NAFLD Activity Score (Percent liver steatosis, inflammation, and fibrosis)6 months

Secondary

MeasureTime frame
Insulin resistance (IR)6 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026